Blood · 2025 · 21 citations · 10 references
MedicineOncologyPharmacologyCell TherapyChemotherapyImmunotherapyCancer ImmunotherapyChemotherapy In Hematologic MalignanciesCytotoxic T Lymphocyte ResponsesHematologic Malignancy TherapyImmunotherapy SafetyTherapy Response AssessmentCell Therapy EfficacyFollow-up DurationLymphoma Treatment ResponsePrimary Efficacy EndpointsPrimary Outcome AnalysisSafety Profile CharacterizationT Cell ExpansionT-cell Therapy
ZUMA-12 is a multicenter phase 2 study evaluating axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy as part of first-line treatment for high-risk large B-cell lymphoma (LBCL). In the primary efficacy analysis (n = 37; median follow-up, 15.9 months), axi-cel demonstrated a high rate of complete responses (CR; 78%) and a safety profile consistent with prior experience. Here, we assessed updated outcomes from ZUMA-12 in 40 treated patients after ≥3 years of follow-up. Eligible adults underwent leukapheresis, lymphodepleting chemotherapy, and axi-cel infusion (2 × 106 CAR T cells/kg). Investigator-assessed CR, objective response, survival, safety, and CAR T-cell expansion were assessed. The CR rate among response-evaluable patients (n = 37) increased after the primary analysis to 86% (95% confidence interval [CI], 71%-95%), with a 92% objective response rate. After a median follow-up of 47.0 months (range, 37.1-57.8 months), 36-month estimates (95% CI) of duration of response and event-free, progression-free, and overall survival were 81.8% (63.9%-91.4%), 73.0% (55.6%-84.4%), 75.1% (57.5%-86.2%), and 81.1% (64.4%-90.5%), respectively. In total, 4 patients had new malignancies, 2 occurring after the data cutoff of the primary analysis; none were axi-cel-related. Eight patients died on study, 2 of whom died from nonrelapse mortality causes. After long-term follow-up, axi-cel demonstrated a high durable response rate, with no new safety signals after the primary analysis, suggestive of an effective first-line therapy with curative intent in high-risk LBCL. Further assessments are needed to determine its benefit vs standard of care. This trial was registered at clinicaltrials.gov, as NCT03761056.
10
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee, Rebecca Gardner, David Porter et al. · Blood · 2014 · 2.8K citations
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Jason R. Westin, Olalekan O. Oluwole, Marie José Kersten et al. · New England Journal of Medicine · 2023 · 410 citations · Full text
Medicine, Immunology, Oncology +17